Multifunctional magnetic resonance imaging probes

Recent Results in Cancer Research

Volumn 187, Issue , 2013, Pages 151-190

  Kluza, Ewelina ^a   Strijkers, Gustav J ^a   Nicolay, Klaas ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; FERUCARBOTRAN; FLUORODEOXYGLUCOSE F 18; FOLATE RECEPTOR; GADOBENATE DIMEGLUMINE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOMELITOL; GADOTERATE MEGLUMINE; GADOTERIDOL; GLUCOCORTICOID; LIPOSOME; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PACLITAXEL; RESOVIST S; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED DRUG RELEASE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG MONITORING; ENCAPSULATION; HUMAN; INTRADUCTAL CARCINOMA; MOLECULAR IMAGING; MULTIFUNCTIONAL MAGNETIC RESONANCE IMAGING PROBE; MULTIPLE CYCLE TREATMENT; NANOEMULSION; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ARTICLE; METHODOLOGY; MOLECULAR PROBE; NEOPLASM; VASCULARIZATION;

HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR PROBES; NEOPLASMS;

EID: 84871831713     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10853-2_5     Document Type: Review

References (192)

1. Abraham SA et al (2002) Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41-54
2. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8(6):464-478
3. Aime S et al (1999) Novel paramagnetic macromolecular complexes derived from the linkage of a macrocyclic Gd(III) complex to polyamino acids through a squaric acid moiety. Bioconjug Chem 10(2):192-199
4. Akazawa K et al (2006) Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12(2):130-137
5. Anderson SA et al (2005) Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105(1):420-425
6. Arbab AS et al (2006) Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 24(3):671-678
7. Arteaga C (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30(3 suppl 7):3-14
8. Artemov D et al (2003a) MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49(3):403-408
9. Artemov D et al (2003b) Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 63(11):2723-2727
10. Avraamides CJ et al (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8(8):604-617
11. Backer MV et al (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 13(4):504-509
12. Barrett T et al (2006) Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 60(3):353-366
13. Barrett T et al (2007) MRI of tumor angiogenesis. J Magn Reson Imaging 26(2):235-249
14. Belli P et al (2006) MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61(11):946-953
15. Bissell MJ, Labarge MA (2005) Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment. Cancer Cell 7(1):17-23
16. Brandwijk RJ et al (2007) Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem 18(3):785-790
17. Brasch RC (1992) New directions in the development of MR imaging contrast media. Radiology 183(1):1-11
18. Brasch RC et al (1994) Quantification of capillary permeability to macromolecular magnetic resonance imaging contrast media in experimental mammary adenocarcinomas. Invest Radiol 29(suppl 2):S8-S11
19. Bremer C, Weissleder R (2001) In vivo imaging of gene expression. Acad Radiol 8(1):15-23
20. Brooks PC et al (1994) Requirement of vascular integrin avb3 for angiogenesis. Science 264(5158):569-571
21. Bulte JWM(2009) In vivoMRI cell tracking: clinical studies. AJRAmJ Roentgenol 193(2):314-325
22. Cai W et al (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47(12):2048-2056
23. Cai W et al (2008) Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 35(1):186-208
24. Caravan P et al (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99(9):2293-2352
25. Caride VJ et al (1984) Relaxation enhancement using liposomes carrying paramagnetic species. Magn Reson Imaging 2(2):107-112
26. Chang YC et al (2004) Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol 49(16):3593-3602
27. Chen JW et al (2004) Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn Reson Med 52(5):1021-1028
28. Chen W et al (2010) Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up. Magn Reson Imaging 28(5):613-620
29. Chenevert TL et al (1997) Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3(9):1457-1466
30. Chenevert TL et al (2002) Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1(4):336-343
31. Chiu GNC et al (2005) Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Cont Release 104(2):271-288
32. Choi H et al (2004) Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 11(9):996-1004
33. ClinicalTrials.gov. U.S. National Institutes of Health [cited. Available from http://clinicaltrials.gov]
34. Cohen FM et al (1994) Contrast-enhanced magnetic resonance imaging estimation of altered capillary permeability in experimental mammary carcinomas after X-irradiation. Invest Radiol 29(11):970-977
35. Corot C et al (2008) Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med 60(6):1337-1346
36. Dafni H et al (2003) Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin. Magn Reson Med 50(5):904-914
37. Dafni H et al (2008) Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-plateletderived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 60(4):822-833
38. Daldrup H et al (1998) Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 171(4):941-949
39. Daldrup-Link HE, Brasch RC (2003) Macromolecular contrast agents for MR mammography: current status. Eur Radiol 13(2):354-365
40. de Lussanet QG et al (2005) Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 235(1):65-72
41. de Schepper AM, Bloem JL (2007) Soft tissue tumors: grading, staging, and tissue-specific diagnosis. Top Magn Reson Imaging 18(6):431-444
42. de Smet M et al (2010) Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J Cont Release 143(1):120-127
43. de Vries AF et al (2003) Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56(4):958-965
44. de Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200(4): 429-447
45. Des Guetz G et al (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94(12):1823-1832
46. Detre JA, Alsop DC (1999) Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur J Radiol 30(2):115-124
47. Detre JA et al (2009) Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 22(4):348-355
48. Devoisselle JM et al (1988) Entrapment of gadolinium-DTPA in liposomes. Characterization of vesicles by P-31 NMR spectroscopy. Invest Radiol 23(10):719-724
49. Drummond DC et al (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691-743
50. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967-974
51. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21): 1182-1186
52. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 suppl 16):15-18
53. Fossheim SL et al (1999) Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. Magn Reson Imaging 17(1):83-89
54. Fossheim SL et al (2000) Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad Radiol 7(12):1107-1115
55. Gabizon AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52(4):891-896
56. Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7(2):223-225
57. Gilead A et al (2004) The role of angiogenesis, vascular maturation, regression and stroma infiltration in dormancy and growth of implanted MLS ovarian carcinoma spheroids. Int J Cancer 108(4):524-531
58. Ginsburg GS, McCarthy JJ (2001) Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 19(12):491-496
59. Granot D et al (2005) Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging. Magn Reson Med 54(4):789-797
60. Granot D et al (2007) In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res 67(19):9180-9189
61. Greish K (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 15(7-8):457-464
62. Grenier N et al (2009) Molecular MR imaging and MR-guided ultrasound therapies in cancer. JBR-BTR 92(1):8-12
63. Griffioen AW et al (2001) Anginex, a designed peptide that inhibits angiogenesis. Biochem J 354(Pt 2):233-242
64. Guccione S et al (2004a) Vascular-targeted nanoparticles for molecular imaging and therapy. Methods Enzymol 386:219-236
65. Guccione S et al (2004b) Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents. IEEE Eng Med Biol Mag 23(5):50-56
66. Haacke EM et al (1999) Magnetic resonance imaging: physical principles and sequence design. John Wiley & Sons, New York
67. Hak S et al (2009) A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm 72(2):397-404
68. He T et al (2011) Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas. J Cell Mol Med 15(4):837-849
69. Helbich TH et al (2000) A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics. J Magn Reson Imaging 11(6):694-701
70. Heusner TA et al (2010) Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 37(6):1077-1086
71. Holgate ST (2010) Exposure, uptake, distribution and toxicity of nanomaterials in humans. J Biomed Nanotechnol 6(1):1-19
72. Hudgins PA et al (2002) Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 23(4):649-656
73. Idee JM et al (2009) Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47(5):855-869
74. Islam T, Harisinghani MG (2009) Overview of nanoparticle use in cancer imaging. Cancer Biomark 5(2):61-67
75. Issa B et al (1999) Heterogeneity analysis of Gd-DTPA uptake: improvement in breast lesion differentiation. J Comput Assist Tomogr 23(4):615-621
76. Jackson A et al (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13(12):3449-3459
77. Joralemon MJ et al (2010) PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun (Camb) 46(9):1377-1393
78. Kabalka GW et al (1991) Gadolinium-labeled liposomes containing various amphiphilic Gd- DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson Med 19(2):406-415
79. Kaneda MM et al (2009) Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng 37(10):1922-1933
80. Kimura H et al (2006) Perfusion imaging of meningioma by using continuous arterial spinlabeling: comparison with dynamic susceptibility-weighted contrast-enhanced MR images and histopathologic features. AJNR Am J Neuroradiol 27(1):85-93
81. Klibanov AL et al (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268(1):235-237
82. Kluza E et al (2009) Novel anti-tumor therapy with liposomal glucocorticoids: MRI monitoring of drug delivery. Paper read at European society for magnetic resonance in medicine and biology congress, at Antalya
83. Kluza E et al (2010) Synergistic targeting of avb3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 10(1):52-58
84. Kluza E et al (2012) Dual-targeting of avb3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Cont Release 158(2): 207-214
85. 2+ ions in solutions of phosphatidylserine vesicles. Magn Reson Med 7(2):133-142
86. Koeppen HK et al (2001) Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38(2):96-104
87. Kok MB et al (2009) Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. Magn Reson Med 61(5):1022-1032
88. Konda SD et al (2000) Development of a tumor-targeting MR contrast agent using the highaffinity folate receptor: work in progress. Invest Radiol 35(1):50-57
89. Konda SD et al (2002) Biodistribution of a 153 Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol 37(4):199-204
90. Kovar DA et al (1998) A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging 8(5):1126-1134
91. Kuhl CK et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions. Radiology 211(1):101-110
92. Kwee TC et al (2009) Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol 70(3):409-417
93. Lanza GM et al (2010) Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 13(2):189-202
94. Leach MO et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92(9):1599-1610
95. Leclercq F et al (2003) Design, synthesis, and evaluation of gadolinium cationic lipids as tools for biodistribution studies of gene delivery complexes. Bioconjug Chem 14(1):112-119
96. Levine DH et al (2008) Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods 46(1):25-32
97. Lijowski M et al (2009) High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol 44(1):15-22
98. Louie AY et al (2000) In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 18(3):321-325
99. Low PS et al (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41(1):120-129
100. Lüdemann L et al (2006) BOLD signal in the motor cortex shows a correlation with the blood volume of brain tumors. J Magn Reson Imaging 23(4):435-443
101. Ma LL et al (2009) Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS Nano 3(9):2686-2696
102. Magin RL et al (1986) Liposome delivery of NMR contrast agents for improved tissue imaging. Magn Reson Med 3(3):440-447
103. Manton DJ et al (2006) Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94(3):427-435
104. Martincich L et al (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83(1):67-76
105. Mayr NA et al (2000) Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12(6):1027-1033
106. McAteer MA et al (2008) Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol 28(1):77-83
107. McCarthy JR et al (2007) Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond) 2(2):153-167
108. Medarova Z et al (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13(3):372-377
109. Medarova Z et al (2009) Development and application of a dual-purpose nanoparticle platform for delivery and imaging of siRNA in tumors. Methods Mol Biol 555:1-13
110. Meisamy S et al (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo 1H MR spectroscopy-a pilot study at 4 T. Radiology 233(2):424-431
111. Meyer D et al (1994) Paramagnetic dextrans as magnetic resonance blood pool tracers. Invest Radiol 29(suppl 2):S90-S92
112. Michel SCA et al (2002) Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225(2):527-536
113. Mikhaylova M et al (2009) Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther 16(3):217-226
114. Mills SJ et al (2006) Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma. AJNR Am J Neuroradiol 27(4):853-858
115. Moffat BA et al (2006) Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 12(5):1525-1532
116. Mulder WJ et al (2004) A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem 15(4):799-806
117. Mulder WJ et al (2005) MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 19(14):2008-2010
118. Mulder WJ et al (2006) Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 19(1):142-164
119. Mulder WJ et al (2009) Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res 42(7):904-914
120. Nahrendorf M et al (2008) Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 117(9):1153-1160
121. Nasongkla N et al (2006) Multifunctional polymeric micelles as cancer-targeted, MRIultrasensitive drug delivery systems. Nano Lett 6(11):2427-2430
122. Navon G et al (1986) Liposomes containing paramagnetic macromolecules as MRI contrast agents. Magn Reson Med 3(6):876-880
123. Neeman M et al (2007) Molecular imaging of angiogenesis. J Magn Reson Imaging 25(1):1-12
124. O'Connor JPB et al (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96(2):189-195
125. Ogan MD et al (1987) Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 22(8):665-671
126. Oliver M et al (2006) MAGfect: a novel liposome formulation for MRI labelling and visualization of cells. Org Biomol Chem 4(18):3489-3497
127. Opsahl LR et al (1995) Tumor imaging with a macromolecular paramagnetic contrast agent: gadopentetate dimeglumine-polylysine. Acad Radiol 2(9):762-767
128. Oyewumi MO, Mumper RJ (2002) Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjug Chem 13(6):1328-1335
129. Ozdemir V et al (2006) Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 24(8):942-946
130. Padhani AR et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102-125
131. Parikh T et al (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246(3):812-822
132. Pochon S et al (2010) BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 45(2):89-95
133. Ponce AM et al (2007) Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 99(1):53-63
134. Preul MC et al (2000) Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrentmalignant gliomas to tamoxifen chemotherapy.Neurosurgery 46(2):306-318
135. Robinson SP et al (1997) The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. Br J Cancer 75(7):1000-1006
136. Ross BD et al (2003) Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2(6):581-587
137. Rottey S et al (2007) Radiolabelled chemotherapeutics. Q J Nucl Med Mol Imaging 51(2):139-151
138. Santra S et al (2009) Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 5(16):1862-1868
139. Saul JM et al (2006) A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 114(3):277-287
140. Schiffelers RM et al (2005) Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7(2):118-127
141. Schmieder AH et al (2008) Three-dimensional MR mapping of angiogenesis with a5b1(avb3)- targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J 22(12):4179-4189
142. Schmiedl U et al (1987) Magnetic resonance imaging of myocardial infarction using albumin- (Gd-DTPA), a macromolecular blood-volume contrast agent in a rat model. Invest Radiol 22(9):713-721
143. Schwarz AJ et al (2002) Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br J Radiol 75(900):959-966
144. Schwickert HC et al (1996) Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 198(3):893-898
145. Semple SI et al (2006) Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 17(9):1393-1398
146. Shames DM et al (1993) Measurement of capillary permeability tomacromolecules by dynamicmagnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 29(5):616-622
147. Shiftan L et al (2005) Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. Cancer Res 65(22):10316-10323
148. Shubayev VI et al (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61(6):467-477
149. Shukla-Dave A et al (2002) Prediction of treatment response of head and neck cancers with P-31MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol 9(6):688-694
150. Shweiki D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843-845
151. Shweiki D et al (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A 92(3):768-772
152. Silva AC et al (2000) Imaging blood flow in brain tumors using arterial spin labeling. Magn Reson Med 44(2):169-173
153. Sinha S et al (2002) In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging 15(6):693-704
154. Sipkins DA et al (1998) Detection of tumor angiogenesis in vivo by avb3-targeted magnetic resonance imaging. Nat Med 4(5):623-626
155. Sirol M et al (2004) Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 109(23):2890-2896
156. Slamon DJ et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182
157. Soman NR et al (2009) Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 119(9):2830-2842
158. Sonvico F et al (2005) Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem 16(5):1181-1188
159. Storrs RW et al (1995) Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imaging 5(6):719-724
160. Strijkers GJ et al (2005) Relaxivity of liposomal paramagnetic MRI contrast agents. Magn Reson Mater Phy 18(4):186-192
161. Strijkers GJ et al (2007) MRI contrast agents: current status and future perspectives. Anti-Cancer Agents Med Chem 7:291-305
162. Strijkers GJ et al (2009) Three-compartment T1 relaxation model for intracellular paramagnetic contrast agents. Magn Reson Med 61(5):1049-1058
163. Strijkers GJ et al (2010) Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis 13(2):161-173
164. Su MY et al (1998) Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn Reson Med 39(2):259-269
165. Suwa T et al (1998) Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 75(4):626-634
166. Taouli B et al (2003) Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226(1):71-78
167. Terreno E et al (2006) Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons. Magn Reson Med 55(3):491-497
168. Thijssen VL et al (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 103(43):15975-15980
169. Thoeny HC et al (2005) Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234(3):756-764
170. Tilcock C et al (1989) Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 171(1):77-80
171. Tofts PS et al (1999)Estimating kinetic parameters fromdynamic contrast-enhanced T1-weightedMRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3):223-232
172. Torchilin VP (2007) Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS Journal 9(2):E128-E147
173. Tropres I et al (2001) Vessel size imaging. Magn Reson Med 45(3):397-408
174. Turetschek K et al (2001) MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging 14(3):237-242
175. Turnbull LW (2009) Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 22(1):28-39
176. Unger E et al (1988) Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress. Invest Radiol 23(12):928-932
177. van der Schaft DW et al (2002) The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 16(14):1991-1993
178. van Tilborg GA et al (2008a) Improvedmagnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia 10(12):1459-1469
179. van Tilborg GA et al (2008b) Kinetics of avidin-induced clearance of biotinylated bimodal liposomes for improved MR molecular imaging. Magn Reson Med 60(6):1444-1456
180. Viglianti BL et al (2004) In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51(6):1153-1162
181. Viglianti BL et al (2006) Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med 56(5):1011-1018
182. Weidner N et al (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1-8
183. Wiener EC et al (1997) Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol 32(12):748-754
184. Willmann JK et al (2008) Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 248(3):936-944
185. Winter PM et al (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel avb3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63(18):5838-5843
186. Winter PM et al (2008) Minute dosages of avb3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J 22(8):2758-2767
187. Wolf RL et al (2005) Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 22(4):475-482
188. Woodhams R et al (2005) Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 29(5):644-649
189. Wu B et al (2006) In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J 21(4):258-264
190. Yang L et al (2009) Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5(2):235-243
191. Zhao M et al (2003) Magnetic sensors for protease assays. Angew Chem Int Ed Engl 42(12):1375-1378
192. Zhu W et al (2008) PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 59(4):679-685